The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study
Background: The relationship between coronavirus disease 2019 (COVID-19) infection and multiple sclerosis (MS) relapse and disease progression remains unclear. Previous studies are limited by small sample sizes and most lack a propensity-matched control cohort. Objective: To evaluate the effect of C...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864241278496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850198258406653952 |
|---|---|
| author | David Levitz Yi Chao Foong Paul Sanfilippo Tim Spelman Louise Rath Angie Roldan Anoushka Lal Mastura Monif Vilija Jokubaitis Serkan Ozakbas Raed Alroughani Cavit Boz Murat Terzi Tomas Kalincik Yolanda Blanco Matteo Foschi Andrea Surcinelli Katherine Buzzard Olga Skibina Guy Laureys Liesbeth Van Hijfte Cristina Ramo-Tello Aysun Soysal Jose Luis Sanchez-Menoyo Mario Habek Elisabetta Cartechini Juan Ignacio Rojas Rana Karabudak Barbara Willekens Talal Al-Harbi Yara Fragoso Tamara Castillo-Triviño Danny Decoo Maria Cecilia Aragon de Vecino Eli Skromne Carmen-Adella Sirbu Chao Zhu Daniel Merlo Melissa Gresle Helmut Butzkueven Anneke Van Der Walt |
| author_facet | David Levitz Yi Chao Foong Paul Sanfilippo Tim Spelman Louise Rath Angie Roldan Anoushka Lal Mastura Monif Vilija Jokubaitis Serkan Ozakbas Raed Alroughani Cavit Boz Murat Terzi Tomas Kalincik Yolanda Blanco Matteo Foschi Andrea Surcinelli Katherine Buzzard Olga Skibina Guy Laureys Liesbeth Van Hijfte Cristina Ramo-Tello Aysun Soysal Jose Luis Sanchez-Menoyo Mario Habek Elisabetta Cartechini Juan Ignacio Rojas Rana Karabudak Barbara Willekens Talal Al-Harbi Yara Fragoso Tamara Castillo-Triviño Danny Decoo Maria Cecilia Aragon de Vecino Eli Skromne Carmen-Adella Sirbu Chao Zhu Daniel Merlo Melissa Gresle Helmut Butzkueven Anneke Van Der Walt |
| author_sort | David Levitz |
| collection | DOAJ |
| description | Background: The relationship between coronavirus disease 2019 (COVID-19) infection and multiple sclerosis (MS) relapse and disease progression remains unclear. Previous studies are limited by small sample sizes and most lack a propensity-matched control cohort. Objective: To evaluate the effect of COVID-19 infection on MS disease course with a large propensity-matched cohort. Design: This multi-centre cohort study analysed relapse and disability outcomes post-COVID-19 infection after balancing covariates using a propensity score matching method. The study period was from the 11th of September 2019 to the 16th of February 2023. The mean follow-up period was 1.7 years. Methods: Data were retrieved from the MSBase Registry. Propensity scores were obtained based on age, sex, disease duration, baseline Expanded Disability Status Scale (EDSS), MS course, relapses pre-baseline, disease-modifying therapy (DMT) class and country. Primary outcomes were time to first relapse, annualised relapse rate (ARR) and time to confirm EDSS progression. Secondary outcomes were time to EDSS of 3, 4 or 6. Sensitivity analyses with baseline DMT classes were performed. Results: The study included 2253 cases and 6441 controls. After matching, there were 2161 cases and an equal number of matched controls. Cases had a significantly higher ARR (ARR = 0.10 [95% CI 0.09–0.11]) compared to controls (ARR = 0.07 [95% CI 0.06–0.08]). Cases had a significantly greater hazard of time to first relapse compared to controls (hazard ratio (HR) = 1.54 [95% CI 1.29–1.84]). There was no association between COVID-19 infection and 24-week EDSS progression (HR = 1.18 [95% CI 0.92–1.52]), or time to EDSS of 3, 4 or 6. For patients on interferons and glatiramer acetate (BRACE), COVID-19 infection was associated with a greater hazard of time to first relapse (HR = 1.83 [95% CI 1.25–2.68]) and greater hazard of time to EDSS of 3 (HR = 2.04 [95% CI 1.06–3.90]) compared to patients on BRACE therapy without COVID-19 infection. Conclusion: COVID-19 infection was associated with a significantly increased MS relapse rate and a shorter time to first relapse. There was no effect on confirmed EDSS progression over the short term. These results support ongoing COVID-19 risk minimisation strategies to protect patients with MS. |
| format | Article |
| id | doaj-art-d14c57df518242b68f0d1c85d8a57657 |
| institution | OA Journals |
| issn | 1756-2864 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj-art-d14c57df518242b68f0d1c85d8a576572025-08-20T02:12:55ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642024-11-011710.1177/17562864241278496The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid LevitzYi Chao FoongPaul SanfilippoTim SpelmanLouise RathAngie RoldanAnoushka LalMastura MonifVilija JokubaitisSerkan OzakbasRaed AlroughaniCavit BozMurat TerziTomas KalincikYolanda BlancoMatteo FoschiAndrea SurcinelliKatherine BuzzardOlga SkibinaGuy LaureysLiesbeth Van HijfteCristina Ramo-TelloAysun SoysalJose Luis Sanchez-MenoyoMario HabekElisabetta CartechiniJuan Ignacio RojasRana KarabudakBarbara WillekensTalal Al-HarbiYara FragosoTamara Castillo-TriviñoDanny DecooMaria Cecilia Aragon de VecinoEli SkromneCarmen-Adella SirbuChao ZhuDaniel MerloMelissa GresleHelmut ButzkuevenAnneke Van Der WaltBackground: The relationship between coronavirus disease 2019 (COVID-19) infection and multiple sclerosis (MS) relapse and disease progression remains unclear. Previous studies are limited by small sample sizes and most lack a propensity-matched control cohort. Objective: To evaluate the effect of COVID-19 infection on MS disease course with a large propensity-matched cohort. Design: This multi-centre cohort study analysed relapse and disability outcomes post-COVID-19 infection after balancing covariates using a propensity score matching method. The study period was from the 11th of September 2019 to the 16th of February 2023. The mean follow-up period was 1.7 years. Methods: Data were retrieved from the MSBase Registry. Propensity scores were obtained based on age, sex, disease duration, baseline Expanded Disability Status Scale (EDSS), MS course, relapses pre-baseline, disease-modifying therapy (DMT) class and country. Primary outcomes were time to first relapse, annualised relapse rate (ARR) and time to confirm EDSS progression. Secondary outcomes were time to EDSS of 3, 4 or 6. Sensitivity analyses with baseline DMT classes were performed. Results: The study included 2253 cases and 6441 controls. After matching, there were 2161 cases and an equal number of matched controls. Cases had a significantly higher ARR (ARR = 0.10 [95% CI 0.09–0.11]) compared to controls (ARR = 0.07 [95% CI 0.06–0.08]). Cases had a significantly greater hazard of time to first relapse compared to controls (hazard ratio (HR) = 1.54 [95% CI 1.29–1.84]). There was no association between COVID-19 infection and 24-week EDSS progression (HR = 1.18 [95% CI 0.92–1.52]), or time to EDSS of 3, 4 or 6. For patients on interferons and glatiramer acetate (BRACE), COVID-19 infection was associated with a greater hazard of time to first relapse (HR = 1.83 [95% CI 1.25–2.68]) and greater hazard of time to EDSS of 3 (HR = 2.04 [95% CI 1.06–3.90]) compared to patients on BRACE therapy without COVID-19 infection. Conclusion: COVID-19 infection was associated with a significantly increased MS relapse rate and a shorter time to first relapse. There was no effect on confirmed EDSS progression over the short term. These results support ongoing COVID-19 risk minimisation strategies to protect patients with MS.https://doi.org/10.1177/17562864241278496 |
| spellingShingle | David Levitz Yi Chao Foong Paul Sanfilippo Tim Spelman Louise Rath Angie Roldan Anoushka Lal Mastura Monif Vilija Jokubaitis Serkan Ozakbas Raed Alroughani Cavit Boz Murat Terzi Tomas Kalincik Yolanda Blanco Matteo Foschi Andrea Surcinelli Katherine Buzzard Olga Skibina Guy Laureys Liesbeth Van Hijfte Cristina Ramo-Tello Aysun Soysal Jose Luis Sanchez-Menoyo Mario Habek Elisabetta Cartechini Juan Ignacio Rojas Rana Karabudak Barbara Willekens Talal Al-Harbi Yara Fragoso Tamara Castillo-Triviño Danny Decoo Maria Cecilia Aragon de Vecino Eli Skromne Carmen-Adella Sirbu Chao Zhu Daniel Merlo Melissa Gresle Helmut Butzkueven Anneke Van Der Walt The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study Therapeutic Advances in Neurological Disorders |
| title | The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study |
| title_full | The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study |
| title_fullStr | The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study |
| title_full_unstemmed | The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study |
| title_short | The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study |
| title_sort | impact of covid 19 infection on multiple sclerosis disease course across 12 countries a propensity score matched cohort study |
| url | https://doi.org/10.1177/17562864241278496 |
| work_keys_str_mv | AT davidlevitz theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yichaofoong theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT paulsanfilippo theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT timspelman theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT louiserath theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT angieroldan theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT anoushkalal theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT masturamonif theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT vilijajokubaitis theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT serkanozakbas theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT raedalroughani theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT cavitboz theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT muratterzi theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT tomaskalincik theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yolandablanco theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT matteofoschi theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT andreasurcinelli theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT katherinebuzzard theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT olgaskibina theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT guylaureys theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT liesbethvanhijfte theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT cristinaramotello theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT aysunsoysal theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT joseluissanchezmenoyo theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT mariohabek theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT elisabettacartechini theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT juanignaciorojas theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT ranakarabudak theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT barbarawillekens theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT talalalharbi theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yarafragoso theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT tamaracastillotrivino theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT dannydecoo theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT mariaceciliaaragondevecino theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT eliskromne theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT carmenadellasirbu theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT chaozhu theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT danielmerlo theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT melissagresle theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT helmutbutzkueven theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT annekevanderwalt theimpactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT davidlevitz impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yichaofoong impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT paulsanfilippo impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT timspelman impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT louiserath impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT angieroldan impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT anoushkalal impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT masturamonif impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT vilijajokubaitis impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT serkanozakbas impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT raedalroughani impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT cavitboz impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT muratterzi impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT tomaskalincik impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yolandablanco impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT matteofoschi impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT andreasurcinelli impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT katherinebuzzard impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT olgaskibina impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT guylaureys impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT liesbethvanhijfte impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT cristinaramotello impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT aysunsoysal impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT joseluissanchezmenoyo impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT mariohabek impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT elisabettacartechini impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT juanignaciorojas impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT ranakarabudak impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT barbarawillekens impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT talalalharbi impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT yarafragoso impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT tamaracastillotrivino impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT dannydecoo impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT mariaceciliaaragondevecino impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT eliskromne impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT carmenadellasirbu impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT chaozhu impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT danielmerlo impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT melissagresle impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT helmutbutzkueven impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy AT annekevanderwalt impactofcovid19infectiononmultiplesclerosisdiseasecourseacross12countriesapropensityscorematchedcohortstudy |